Targeting ALK in patients with advanced Non Small Cell Lung Cancer: Biology, diagnostic and therapeutic options

Critical Reviews in Oncology/Hematology

Volumn 89, Issue 3, 2014, Pages 358-365

  Lazzari, Chiara ^a   Spitaleri, Gianluca ^a   Catania, Chiara ^a   Barberis, Massimo ^a   Noberasco, Cristina ^a   Santarpia, Mariacarmela ^a   Delmonte, Angelo ^a   Toffalorio, Francesca ^a   Conforti, Fabio ^a   De Pas, Tommaso Martino ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Crizotinib; EML4 ALK fusion gene; Non Small Cell Lung Cancer

Indexed keywords

CRIZOTINIB; EML4-ALK FUSION GENE; NON SMALL CELL LUNG CANCER;

CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; CARBOPLATIN; CERITINIB; CISPLATIN; CRIZOTINIB; DOCETAXEL; GANETESPIB; LUMINESPIB; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; RETASPIMYCIN; RO 5424802; UNCLASSIFIED DRUG; [2 [[5 CHLORO 2 [[4 [4 (DIMETHYLAMINO) 1 PIPERIDINYL] 2 METHOXYPHENYL]AMINO] 4 PYRIMIDINYL]AMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE;

ADVANCED CANCER; CANCER PATIENT; CANCER THERAPY; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG COST; DRUG RESISTANCE; DRUG TARGETING; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN 4 GENE; FATIGUE; FOOD AND DRUG ADMINISTRATION; FUSION GENE; GENE; HUMAN; LIVER TOXICITY; NAUSEA; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; REVIEW; VISUAL DISORDER; VOMITING;

EID: 84893775144     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.09.003     Document Type: Review

References (53)

1. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non small cell lung cancer. Nature 2007, 448:561-566.
2. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non small cell lung cancer. N Engl J Med 2010, 363:1693-1703.
3. Camidge D.R., Bang Y.J., Kwak E.L., et al. Activity and safety of crizotinib in patients with ALK positive non small cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13:1011-1019.
4. Shaw A.T., Kim D.W., Nakagawa K., et al. Crizotinib versus chemotherapy in advanced ALK positive lung cancer. N Engl J Med 2013, 25:2385-2394.
5. Chiarle R., Voena C., Ambrogio C., et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008, 1:11-23.
6. Sanders H.R., Li H.R., Bruey J.M., et al. Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Cancer Genet 2011, 1:45-52.
7. Wang R., Pan Y., Li C., et al. The use of quantitative real time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res 2012, 17:4725-4732.
8. Takeuchi K., Choi Y.L., Soda M., et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008, 14:6618-6624.
9. Choi Y.L., Takeuchi K., Soda M., et al. Identification of novel isoforms of the EML4-ALK transforming gene in non small cell lung cancer. Cancer Res 2008, 68:4971-4976.
10. Horn L., Pao W. EML4-ALK. Honing in on a new target in Non Small Cell Lung Cancer. J Clin Oncol 2009, 27:4232-4235.
11. Sasaki T., Rodig S.J., Chirieac L.R., et al. The biology and treatment of EML4-ALK Non Small Cell Lung Cancer. Eur J Cancer 2010, 46:1773-1780.
12. Takeuchi K., Choi Y.L., Togashi Y., et al. KIKF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry based diagnostic system for ALK positive lung cancer. Clin Cancer Res 2009, 15:3143-3149.
13. Shaw A.T., Yeap B.Y., Mino-Kenudson M., et al. J Clin Oncol 2009, 10:4247-4253.
14. Inamura K., Takeuchi K., Togashi Y., et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008, 3:13-17.
15. Inamura K., Takeuchi K., Togashi Y., et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset. Mod Pathol 2009, 22:508-515.
16. Wong D.W., Leung E.L., So K.K., et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009, 115:1723-1733.
17. Heuckmann J.M., Balke-Want H., Malchers F., et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res 2012, 1:4682-4690.
18. Wallander M.L., Geiersbach K.B., Tripp S.R., Layfield L.J. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med 2012, 136:796-803.
19. Soda M., Isobe K., Inoue A., et al. A prospective PCR based screening for the EML4-ALK oncogene in non small cell lung cancer. Clin Cancer Res 2012, 15:5682-5689.
20. Wang R., Pan Y., Li C., et al. The use of quantitative real time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res 2012, 1:4725-4732.
21. Mino-Kenudson M., Chirieac L.R., Law K., et al. A novel, highly sensitive antibody allows for the routine detection of ALK rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010, 16:1561-1571.
22. McLeer-Florin A., Moro-Sibilot D., Melis A., et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 2012, 7:348-354.
23. Paik J.H., Choe G., Kim H., et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011, 6:466-472.
24. Park H.S., Lee J.K., Kim D.W., et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 2012, 77:288-292.
25. Selinger C.I., Rogers T.M., Russell P.A., et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2013, (June). 10.1038/modpathol.2013.87.
26. Sun J.M., Choi Y.L., Won J.K., et al. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. J Thorac Oncol 2012, 7:e36-e38.
27. Kim D., Ahn M., Yang P., et al. Updated results of a global Phase II study with crizotinib in advanced Alk positive NSCLC. Ann Oncol 2012, 23(Suppl 9):ixe402.
28. Ramalingam S.S., Shaw A.T. Hypogonadism related to crizotinib therapy: implications for patient care. Cancer 2012, 1:21.
29. Weickhardt A.J., Rothman M.S., Salian-Mehta S., et al. rapid onset hypogonadism secondary to crizotinib use in metastatic non small cell lung cancer. Cancer 2012, 118:5302-5309.
30. Katayama R., Shaw A.T., Khan T.M., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012, 120:120ra17.
31. Doebele R.C., Pilling A.B., Aisner D.L., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non small cell lung cancer. Clin Cancer Res 2012, 5:1472-1482.
32. Choi Y.L., Soda M., Yamashita Y., et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010, 363:1734-1739.
33. Lovly C.M., Pao W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci Transl Med 2012, 120:120ps2.
34. Sun H.Y., Ji F.Q. A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK. Biochem Biophys Res Commun 2012, 2:319-324.
35. Sasaki T., Koivunen J., Ogino A., et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011, 18:6051-6060.
36. Heuckmann J.M., Hölzel M., Sos M.L., et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 2011, 23:7394-7401.
37. Weickhardt A.J., Scheier B., Burke J.M., et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012, 12:1807-1814.
38. Costa D.B., Kobayashi S., Pandya S.S., et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011, 15:e443-e445.
39. Gettinger S., Weiss G.J., Salgia R., et al. A first in human dose finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies. Ann Oncol 2012, (Suppl. 9):ix152-ix174.
40. Marsilje T.H., Pei W., Chen B., et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonylphenyl) pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 2013, [Epub ahead of print].
41. Shaw A.T., Camidge D.R., Felip E., et al. Results of a first in human Phase I study of the ALK inhibitor LDK378 in advanced solid tumors. Ann Oncol 2012, (suppl 9):ix152-ix174.
42. Sakamoto H., Tsukaguchi T., Hiroshima S., et al. CH5424802, a selective ALK Inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011, 18:6286-6294.
43. Kinoshita K., Asoh K., Furuichi N., et al. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). Bioorg Med Chem 2012, 3:1271-1280.
44. Seto T., Kiura K., Nishio M., et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013, 7:590-598.
45. Chen Z., Sasaki T., Tan X., et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 2010, 23:9827-9836.
46. Normant E., Paez G., West K.A., et al. The Hsp90 inhibitor IPI 504 rapidly lowers EML4-ALK levels and induces tumour regression in ALK driven NSCLC models. Oncogene 2011, 22:2581-2586.
47. Sequist L.V., Gettinger S., Senzer N., et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined Non Small Cell lung Cancer. J Clin Oncol 2010, 28:4953-4960.
48. Socinski M.A., Goldman J., El-Hariry I., et al. A multicenter Phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 2013, 11:3068-3077.
49. Felip E., Carcereny E., Barlesi F., et al. Phase II activity of the Hsp90 inhibitor AUY922 in patients with ALK rearranged (ALK+) or EGFR mutated advanced non small cell lung cancer (NSCLC). Ann Oncol 2012, (Suppl. 9):ix152-ix174.
50. Zhang S., Wang F., Keats J., et al. Crizotinib resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des 2011, 6:999-1005.
51. Chmielecki J., Foo J., Oxnard G.R., et al. Optimization of dosing for EGFR mutant non small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011, 90:90ra59.
52. Camidge D.R., Kono S.A., Lu X., et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011, 6:774-780.
53. Lee J.O., Kim T.M., Lee S.H., et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 2011, 6:1474-1480.